may result from ischemia/reperfusion injury, in certain embodiments. In certain embodiments, the RKD results from diabetes or hypertension. The RKD may result from an autoimmune disease. The RKD may be further defined as chronic RKD, or acute RKD.

In certain methods of treating renal/kidney disease (RKD) in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure, the subject has undergone or is undergoing dialysis. In certain embodiments, the subject has undergone or is a candidate to undergo kidney transplant. The subject may be a primate. The primate may be a human. The subject in this or any other method may be, for example, a cow, horse, dog, cat, pig, mouse, rat or guinea pig.

Also contemplated by the present disclosure is a method for improving glomerular filtration rate or creatinine clearance in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of the present disclosure.

In some embodiments, the pharmaceutical composition is administered in a single dose per day. In other embodiments, the pharmaceutical composition is administered in more than one dose per day. In some embodiments, the pharmaceutical composition is administered in a pharmaceutically effective amount.

In some embodiments, the active ingredient is administered in a dose from about 1 mg/kg to about 2000 mg/kg. In other embodiments, the dose is from about 3 mg/kg to about 100 mg/kg. In other embodiments, the dose is about 3, 10, 30, or 100 mg/kg.

In other embodiments, the pharmaceutical composition is administered topically. In some embodiments, the topical administration is administered to the skin. In other embodiments, the topical administration is administered to the eye.

In other embodiments, the pharmaceutical composition is administered orally. In other embodiments, the pharmaceutical composition is administered intraocularly.

In another aspect of the invention, there is provided the use of a therapeutically effective amount of the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating or preventing a condition associated with inflammation or oxidative stress in a patient in need thereof.

In another aspect of the invention, there is provided the use of a therapeutically effective amount of the pharmaceutical composition as described herein in the manufacture of a medicament for treating or preventing a condition associated with inflammation or oxidative stress resulting from abnormally high or prolonged levels of reactive oxygen species in a patient in need thereof, wherein the condition is a skin

disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes.

Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those

26. The pharmaceutical composition of claim 22, wherein the amount of the active ingredient is about 3% by weight.

27. Use of a therapeutically effective amount of the pharmaceutical composition according to any one of claims 9 to 26 in the manufacture of a medicament for treating or preventing a condition associated with inflammation or oxidative stress resulting from abnormally high or prolonged levels of reactive oxygen species in a patient in need thereof, wherein the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes.

28. The use of claim 27, wherein the condition is a skin disease or disorder.

29. The use of claim 28, wherein the skin disease or disorder is dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, epidermolysis bullosa, sunburn, a disorder of skin pigmentation, a post-surgical wound, psoriasis, a dermatological manifestation of an autoimmune disease or a graft-versus host disease, and skin cancer.

30. The use of claim 29, wherein the skin disease or disorder is dermatitis.

31. The use of claim 30, wherein the dermatitis is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis.

32. The use of claim 29, wherein the skin disease or disorder is a chronic wound.

33. The use of claim 32, wherein the chronic wound is a diabetic ulcer, a pressure sore, or a venous ulcer.

34. The use of claim 29, wherein the skin disease or disorder is alopecia.

35. The use of claim 34, wherein the alopecia is selected from baldness and drug-induced alopecia.

36. The use of claim 29, wherein the skin disease or disorder is a disorder of skin pigmentation.

37. The use of claim 36, wherein the disorder of skin pigmentation is vitiligo.

38. The use of claim 29, wherein the disorder involving hyperproliferation of skin cells is hyperkeratosis.

39. The use of claim 27, wherein the condition is an autoimmune disease.

40. The use of claim 39, wherein the condition is rheumatoid arthritis, lupus, Crohn's disease, or psoriasis.

41. The use of claim 27, wherein the condition is liver disease.

42. The use of claim 41, wherein the liver disease is fatty liver disease or hepatitis.

43. The use of claim 27, wherein the condition is an eye disorder.

44. The use of claim 43, wherein the eye disorder is uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis, or a form of conjunctivitis.

45. The use of claim 44, wherein the eye disorder is macular degeneration.

46. The use of claim 45, wherein the macular degeneration is the dry form.

47. The use of claim 45, wherein the macular degeneration is the wet form.

48. The use of claim 44, wherein the disease or disorder of the corneal endothelium is Fuchs endothelial corneal dystrophy.

49. The use of claim 27, wherein the condition is a lung disease.

50. The use of claim 49, wherein the lung disease is pulmonary inflammation, pulmonary fibrosis, COPD, asthma, cystic fibrosis, or idiopathic pulmonary fibrosis.

51. The use of claim 50, wherein the lung disease is pulmonary inflammation.

52. The use of claim 50, wherein the lung disease is pulmonary fibrosis.

53. The use of claim 50, wherein the lung disease is COPD.

54. The use of claim 53, wherein the COPD is induced by cigarette smoke.

55. The use of claim 50, wherein the lung disease is asthma.

56. The use of claim 27, wherein the condition is sepsis.

57. The use of claim 27, wherein the condition is mucositis resulting from radiation therapy or chemotherapy.

58. The use of claim 57, wherein the mucositis presents orally.

59. The use according to any one of claims 27-58, wherein the pharmaceutical composition is to be administered in a single dose per day.

60. The use according to any one of claims 27-58, wherein the pharmaceutical composition is to be administered in more than one dose per day.

61. The use according to any one of claims 27-60, wherein the active ingredient is to be administered in a dose from about 1 mg/kg to about 2000 mg/kg.

62. The use of claim 61, wherein the dose is from about 3 mg/kg to about 100 mg/kg.

63. The use of claim 62, wherein the dose is about 3 mg/kg.

64. The use of claim 62, wherein the dose is about 10 mg/kg.

65. The use of claim 62, wherein the dose is about 30 mg/kg.

66. The use of claim 62, wherein the dose is about 100 mg/kg.

67. The use according to any one of claims 27-58, wherein the pharmaceutical composition is to be administered topically.

68. The use of claim 67, wherein the topical administration is to be administered to the skin.

69. The use of claim 67, wherein the topical administration is to be administered to the eye.

70. The use according to any one of claims 27-58, wherein the pharmaceutical composition is to be administered orally.

71. The use according to any one of claims 27-58, wherein the pharmaceutical composition is to be administered intraocularly.

72. The use according to any one of claims 27-71, wherein the patient is a human.

73. The use according to any one of claims 27-71, wherein the patient is a non-human animal.